Find a Physician | Courier | Events Calendar | Contact Us | Clinical Trials
Select a Cancer Type:

Cancer Center Member

Steven T Rosen, MD

Academic Title:
Director (Academic), Lurie Cancer Center; Feinberg School of Medicine

Member of:
Cancer Cell Biology,Hematologic Malignancies


View Publications Listing

Cancer Focused Research:

Steven Rosen, MD, FACP, is Genevieve Teuton Professor of Medicine, at the Feinberg School of Medicine, Northwestern University and Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Cancer Programs at Northwestern Memorial Hospital. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr. Rosen completed his residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at the National Cancer Institute. Dr. Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies. Dr. Rosen has received numerous grants awards and contracts and has published more than 300 scientific papers. As Director of the Cancer Center, Dr. Rosen has successfully competed for an NCI Cancer Center Support Grant, NCI grants for his laboratory research, an NCI RAID Contract grant for the development of a novel purine analog, and grants from the Leukemia and Lymphoma Society of America and the American Cancer Society.
Dr. Rosen serves on several editorial boards and is editor of Cancer Treatment & Research. He is a member of all major national associations that focus on oncology and has held leadership positions in the Eastern Cooperative Oncology Group, the American Association of Cancer Institutes and the National Comprehensive Cancer Network. He serves on the advisory boards of several NCI-designated Cancer Centers, the Leukemia and Lymphoma Society of America, the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation and the Wendy Will Cancer Research Foundation. He has also served as an advisor to Great Britain's Cancer Research Campaign. Dr. Rosen was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996) and recognition from the Women's Board of Northwestern Memorial Hospital for Compassionate Care (1996) Endowed Weber Lymphoma Lector, UNC (2011), Man of Distinction Award, Israel Cancer Research Fund (2011). He is acknowledged in Best Doctors in America and Best Doctors in Chicago.

Current research efforts are focused on 1) novel RNA directed nucleoside analogs. 8 Chloro and 8 amino adenosine that incorporate and terminate transcription of RNA following conversion to the tri-phosphate moiety. 8 amino also interferes with serine/threonine phosphorylation of a spectrum of proteins. Both selectively effect malignant cells, induce program cell death in a p53 independent manner. 8 Chloro has entered the clinic in a phase 1 trial targeting CLL. Alternative analogs are being developed with our medicinal chemists(Karl Scheidt Core). Nanoconstructs are being developed with Son Binh Nguyen (collaborator Dr. Krett); 2) analysis of glucose metabolism and in particular characterization of glut receptors for glucose transport and demonstration that they are targets for therapy of myeloma, CLL and select non-Hodgkin's lymphomas (collaborator Dr. Shanmugam); 3) study of the regulation of glucocorticoid receptor expression in B cell malignancies (incuding demonstration of miRNA regulation) and its mechanism of action (collaborator Dr. Krett); and 4) analysis of key signalling pathways in cutaneous T cell lymphomas as therapeutic targets including PKCB (characterized mechanism of action of inhibitor, Enzastaurin, and conducted a phase I clinical trial sponsored by Lilly) , AKT, GSK3B, Stat3 and B-catenin (collaborators Drs. Krett, Kuzel, Guitart). Clinical investigations include trials in CLL (eg. alemtuzumab/ofatumimab in CLL ( collaboration with Shuo Ma) and (Romidepsin/Carfilzomib in CTCL with Tim Kuzel).

Related News